The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1130-1132

  Bonanno, L ^a,b   Costa, C ^b   Majem, M ^c   Favaretto, A ^a   Rugge, M ^d   Rosell, R ^e  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF PADOVA   (Italy)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; GEMCITABINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; PEMETREXED; RAP80 PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER PATIENT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LETTER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84875585910     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt063     Document Type: Letter

References (4)

1. Husain A, He G, Venkatraman ES et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58: 1120-1123.
2. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
3. Pierceall WE, Olaussen KA, Rousseau V et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012; 23: 2245-2252.
4. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4: e5133